Detalles de la búsqueda
1.
Characterization and antiviral susceptibility of SARS-CoV-2 Omicron BA.2.
Nature
; 607(7917): 119-127, 2022 07.
Artículo
en Inglés
| MEDLINE | ID: mdl-35576972
2.
Preinfection Neutralizing Antibodies, Omicron BA.5 Breakthrough Infection, and Long COVID: A Propensity Score-Matched Analysis.
J Infect Dis
; 228(12): 1652-1661, 2023 12 20.
Artículo
en Inglés
| MEDLINE | ID: mdl-37756608
3.
Highly Neutralizing COVID-19 Convalescent Plasmas Potently Block SARS-CoV-2 Replication and Pneumonia in Syrian Hamsters.
J Virol
; 96(4): e0155121, 2022 02 23.
Artículo
en Inglés
| MEDLINE | ID: mdl-34818068
4.
Evaluation of darunavir-derived HIV-1 protease inhibitors incorporating P2' amide-derivatives: Synthesis, biological evaluation and structural studies.
Bioorg Med Chem Lett
; 83: 129168, 2023 03 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-36738797
5.
SARS-CoV-2 papain-like protease (PLpro) inhibitory and antiviral activity of small molecule derivatives for drug leads.
Bioorg Med Chem Lett
; 96: 129489, 2023 11 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-37770002
6.
Omicron BA.1 neutralizing antibody response following Delta breakthrough infection compared with booster vaccination of BNT162b2.
BMC Infect Dis
; 23(1): 282, 2023 May 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-37142992
7.
Preserved SARS-CoV-2 neutralizing IgG activity of in-house manufactured COVID-19 convalescent plasma.
Transfus Apher Sci
; 62(3): 103638, 2023 Jun.
Artículo
en Inglés
| MEDLINE | ID: mdl-36610860
8.
Efficacy of convalescent plasma therapy for COVID-19 in Japan: An open-label, randomized, controlled trial.
J Infect Chemother
; 29(9): 869-874, 2023 Sep.
Artículo
en Inglés
| MEDLINE | ID: mdl-37178973
9.
Syrian hamsters as a small animal model for SARS-CoV-2 infection and countermeasure development.
Proc Natl Acad Sci U S A
; 117(28): 16587-16595, 2020 07 14.
Artículo
en Inglés
| MEDLINE | ID: mdl-32571934
10.
Exploratory Studies of Effective Inhibitors against the SARS-CoV-2 Main Protease by Halogen Incorporation and Amide Bond Replacement.
Chem Pharm Bull (Tokyo)
; 71(12): 879-886, 2023.
Artículo
en Inglés
| MEDLINE | ID: mdl-38044140
11.
Coronavirus Disease 2019 (COVID-19) Breakthrough Infection and Post-Vaccination Neutralizing Antibodies Among Healthcare Workers in a Referral Hospital in Tokyo: A Case-Control Matching Study.
Clin Infect Dis
; 75(1): e683-e691, 2022 08 24.
Artículo
en Inglés
| MEDLINE | ID: mdl-34950947
12.
Fluorine Modifications Contribute to Potent Antiviral Activity against Highly Drug-Resistant HIV-1 and Favorable Blood-Brain Barrier Penetration Property of Novel Central Nervous System-Targeting HIV-1 Protease Inhibitors In Vitro.
Antimicrob Agents Chemother
; 66(2): e0171521, 2022 02 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-34978889
13.
Biochemical and Structural Properties of Entecavir-Resistant Hepatitis B Virus Polymerase with L180M/M204V Mutations.
J Virol
; 95(16): e0240120, 2021 07 26.
Artículo
en Inglés
| MEDLINE | ID: mdl-34076480
14.
Effects of a novel hepatitis B anti-viral drug E-CFCP in renal organic acid transporters.
J Pharmacol Sci
; 150(4): 201-203, 2022 Dec.
Artículo
en Inglés
| MEDLINE | ID: mdl-36344041
15.
Antibody titers and neutralizing activity in cases of COVID-19 after a single dose of vaccination.
J Infect Chemother
; 28(12): 1704-1706, 2022 Dec.
Artículo
en Inglés
| MEDLINE | ID: mdl-36067912
16.
Successful use of casirivimab/imdevimab anti-spike monoclonal antibodies to enhance neutralizing antibodies in a woman on anti-CD20 treatment with refractory COVID-19.
J Infect Chemother
; 28(7): 991-994, 2022 Jul.
Artículo
en Inglés
| MEDLINE | ID: mdl-35337728
17.
Neutralising activity and antibody titre in 10 patients with breakthrough infections of the SARS-CoV-2 Omicron variant in Japan.
J Infect Chemother
; 28(9): 1340-1343, 2022 Sep.
Artículo
en Inglés
| MEDLINE | ID: mdl-35644734
18.
Identification of a novel long-acting 4'-modified nucleoside reverse transcriptase inhibitor against HBV.
J Hepatol
; 74(5): 1075-1086, 2021 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-33333207
19.
Development of Human Immunodeficiency Virus Type 1 Resistance to 4'-Ethynyl-2-Fluoro-2'-Deoxyadenosine Starting with Wild-Type or Nucleoside Reverse Transcriptase Inhibitor-Resistant Strains.
Antimicrob Agents Chemother
; 65(12): e0116721, 2021 11 17.
Artículo
en Inglés
| MEDLINE | ID: mdl-34516245
20.
Effects of islatravir (4'-ethynyl-2-fluoro-2'-deoxyadenosine or EFdA) on renal tubular cells and islatravir's interactions with organic anion transporters.
J Pharmacol Sci
; 146(2): 82-87, 2021 Jun.
Artículo
en Inglés
| MEDLINE | ID: mdl-33941324